Indoco Remedies Share Price

Indoco Remedies Limited  is a leading pharmaceutical company in India, primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company supplies products across various therapeutic segments, including acute, chronic, and specialty segments, covering anti-infectives, gastro-intestinal, pain management, ophthalmology, and respiratory therapies. Indoco Remedies operates a vast network of manufacturing facilities and exports to over 55 countries worldwide. The Indoco Remedies share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Indoco Remedies stock price often mirrors shifts in pharmaceutical demand, regulatory approvals from the USFDA and other global agencies, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of ANDA approvals, competitive intensity from other pharma manufacturers, raw material price fluctuations, and government policies on drug pricing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Indoco Remedies stock price movements.

Indoco Remedies live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Indoco Remedies live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Indoco Remedies share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Indoco Remedies Limited Company Fundamentals

a. Company Background

Indoco Remedies Limited was incorporated in 1947. The company’s registered office is located in Mumbai, Maharashtra. The company was founded in 1945 and was formerly known as Indo Continental Trading Company. It was incorporated as a Public Limited Company on August 23, 1947 and is a prominent company in the Indian pharmaceutical industry. Indoco Remedies’ primary activity involves the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). It initially focused on building a strong foothold in the domestic formulation market before gradually expanding into APIs, contract manufacturing, and research. The company launched six new products (SKUs) in a recent year, two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment. Indoco also licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of a profit sharing agreement, Indoco develops, manufactures and supplies a basket of sterile products to Watson for the US market. Over the years, Indoco Remedies has significantly expanded its product portfolio and manufacturing footprint. It operates in a competitive environment, with pricing and production governed by market forces and regulatory frameworks. The company has consistently focused on enhancing its research capabilities to meet the growing demand for quality pharmaceuticals in India and globally.

b. Product Lines

• Pharmaceutical formulations in tablets, capsules, liquids, injectables, and ointments across acute and chronic therapeutic segments.

• Active Pharmaceutical Ingredients (APIs) for various therapeutic categories.

• Generics for domestic and international markets.

• Contract manufacturing services for global pharmaceutical companies.

• Products for anti-infectives, gastro-intestinal, pain management, ophthalmology, and respiratory therapies.

• Specialty products for niche therapeutic areas.

• Products developed through in-house research and development (R&D).

• Products licensed to global partners for the US and other regulated markets.

c. Company Revenue Model

• Primary revenue from the manufacturing and sale of pharmaceutical formulations (Finished Dosage Forms) to domestic and international markets.

• Revenue from the manufacture and sale of Active Pharmaceutical Ingredients (APIs) for use in formulations.

• Volume-driven revenue based on quantity of formulations and APIs supplied across acute, chronic, and specialty segments.

• Pricing determined by raw material costs, product complexity, regulatory approvals, and market demand.

• Revenue from contract manufacturing and research services for global clients.

• Revenue from technology licensing and profit-sharing agreements, including the one with Watson Pharmaceuticals Inc. USA.

• Revenue from both domestic Indian market and exports to over 55 countries worldwide.

• Focus on increasing share of high-value regulated markets including the US and Europe to drive better margins.

• Raw material price fluctuations and regulatory cycles influencing revenue stability.

• Government policies on drug pricing (e.g., National Pharmaceutical Pricing Authority) influencing revenue stability.

d. Geographic Presence

• Headquartered in Mumbai, Maharashtra with registered office at Indoco House, 166.

• Manufacturing facilities located across India with a strong focus on formulations and APIs.

• Strong domestic market presence across India serving patients and healthcare providers.

• Global export presence to over 55 countries around the world.

• Focus on expanding into new geographical areas through enhanced regulatory filings and commercial partnerships.

• Operations primarily concentrated in western India with manufacturing footprint across multiple states.

e. Key Milestones

• 1947: Incorporated as Indoco Remedies Limited on August 23, 1947.

• 2000s: Expanded operations to include API manufacturing and contract research.

• 2024: Total Income stood at 1,536.67 crores in FY25 as compared to 1,799.32 crores in FY24.

• 2025: Reported consolidated sales for the quarter ended December 2025 of ₹446.34 crore.

f. Industry Perspective

Indoco Remedies Limited operates in the pharmaceutical industry, which is part of India’s healthcare sector. Globally, the pharmaceutical market continues to expand with the Asia-Pacific region being the fastest-growing market. In India, the pharmaceutical sector is poised for substantial growth. According to industry reports, the Indian pharmaceutical market was valued at USD 65-70 billion in 2025 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 10-12%. The domestic formulation market accounts for approximately 60-65% of the industry, with exports comprising the remainder. India is the largest provider of generic drugs globally, supplying over 20% of global generic volume. The Indian pharmaceutical industry is well-positioned to sustain 7-9% growth, driven by robust domestic demand, stable export performance, and a steady transition towards complex generics, biosimilars, and specialty products. Demand is driven by rising healthcare spending, increasing chronic disease prevalence, government initiatives like Ayushman Bharat, and growing medical tourism. Key challenges include raw material price volatility (APIs from China), intense competition from domestic and international players, regulatory price controls, and pricing pressure in export markets.

Indoco Remedies Limited Stock Market Presence: Listings & Index Representation

Indoco Remedies is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol INDOCO and on the Bombay Stock Exchange (BSE) with the scrip code 532612. Its listing on both exchanges ensures that the Indoco Remedies price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Indoco Remedies is included in indices such as BSE SmallCap, BSE AllCap, and BSE Healthcare. Being represented in multiple indices enhances the visibility and liquidity of the Indoco Remedies price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Indoco Remedies in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the Indoco Remedies price to corporate and industry developments. The company’s ISIN code is INE873A01025 and face value is ₹2 per share.

Indoco Remedies Limited Stock Performance and Share Price History

The Indoco Remedies price has exhibited significant volatility over the past decade, shaped by the company’s operations in India’s pharmaceutical sector and broader industry cycles. The Indoco Remedies share price recorded a total return of approximately -15.72% over the last 3 years, underperforming the BSE Healthcare index’s 12.5% return over the same period as of April 2026, reflecting near-term headwinds including regulatory challenges and margin pressures. The Indoco Remedies share price reached a 52-week high of ₹351.35 and a 52-week low of ₹177.10, indicating a wide trading range and substantial price fluctuations. The Indoco Remedies share price showed a 1-year return of -14.42% as of February 2026, indicating recent consolidation. As of April 2026, the stock was trading at levels of around ₹213-₹219 on the NSE and BSE.

The Indoco Remedies price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 42.6% year-on-year growth in net profit to ₹28.2 crore in Q2 FY26, the Indoco Remedies stock price showed a positive reaction. The Indoco Remedies price has shown a pattern of strong positive momentum in periods when the company’s ANDA approvals and regulatory clearances exceeded expectations, while periods of earnings moderation or concerns over raw material costs have contributed to consolidation. Corporate developments, including strategic announcements such as the launch of new products, regulatory approvals from global agencies, and the company’s focus on the chronic segment and regulated markets, have also influenced short-term fluctuations in the Indoco Remedies share price. The Indoco Remedies share price has shown a 1-year return of approximately -14.42% as of February 2026, reflecting the modest correction from its 2024 highs. The Indoco Remedies share price has shown a 10-year aggregate net profit that has grown, reflecting the company’s sustained profitability over the long term. The Indoco Remedies share price reached its 52-week high of ₹351.35 before declining to its 52-week low of ₹177.10, reflecting the volatility inherent in the pharma space. The Indoco Remedies share price has shown a year-to-date return that has been negative as of April 2026, indicating pressure in the current fiscal year. Comprehending these patterns in the Indoco Remedies share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Indoco Remedies stock price movements illustrate how industry fundamentals, raw material price cycles, and investor expectations converge in market pricing.

The Indoco Remedies share price has shown distinct seasonal patterns over the past decade. The best performing year historically was 2024 with a positive return, while the worst year was 2025 with a significant decline. In terms of annual performance, the Indoco Remedies share price delivered a 1-year return of 19.34%, a 3-year return of 2.38%, and a 5-year return of 1.35% as per Value Research data. The Indoco Remedies share price has demonstrated that the stock tends to perform better in periods of strong pharmaceutical demand and supportive regulatory frameworks, while underperforming during phases of raw material volatility and intense competition. The Indoco Remedies stock price has shown a 3-year total return of -15.72%, indicating the challenges faced in the pharma sector in recent years. The Indoco Remedies stock price continues to trade at a significant discount from its 52-week high of ₹351.35, standing at around ₹213-₹219 levels as of April 2026.

Indoco Remedies Limited Investor Relevance and Role in Portfolio

Indoco Remedies holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on formulations and APIs. The company’s presence in generics and specialty products aligns it with investment strategies that value healthcare access, affordability, and the government’s focus on domestic pharma manufacturing. The Indoco Remedies share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor regulatory approvals, raw material costs, and product pipeline when evaluating allocation decisions.

Institutional stakeholders play a significant role in Indoco Remedies’s ownership profile. As of December 2025, Promoters hold 46.59% of the company. Mutual funds hold 19.58% of the company. Key mutual fund holders include SBI Small Cap Fund, Kotak Small Cap Fund, HDFC Small Cap Fund, Nippon India Small Cap Fund, and Canara Robeco Small Cap Fund. Foreign Institutional Investors (FIIs) hold 10.00% of the company, while Domestic Institutional Investors (DIIs) hold 1.03%. Institutional investors as a whole hold 30.61% of the company as of December 2025. Retail and other shareholders hold approximately 22.80% of the company. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

Based on data, Indoco Remedies exhibits varying levels of beta and volatility across different measurement periods. Based on data, the long-term beta (1-year) stands at approximately 0.62-0.69, indicating that the stock is generally less volatile than the broader market over an extended period. Based on data, the daily-one month beta shows low correlation, while the daily-three month beta indicates moderate sensitivity. Based on data, the weekly-one year beta shows lower-than-market sensitivity in short-term trading. Based on data, the weekly-two year beta shows low correlation, and the 2 week-two year range beta is also low. Based on data, the monthly-two year beta continues to show moderate correlation. Supporting statistics include mean values across different periods and standard deviations indicating moderate variability. The stock carries a beta of 0.66 as per Equitymaster, indicating it is less volatile than the market. Overall, the Indoco Remedies stock price demonstrates a moderate volatility profile with beta values suggesting the stock tends to move with lower volatility compared to broader market direction over longer time frames.

The Indoco Remedies share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Indoco Remedies stock price’s beta reflects that the company’s established manufacturing capabilities and diverse product portfolio may provide some stability, though the pharmaceutical sector remains sensitive to raw material price fluctuations and regulatory changes.

Indoco Remedies Limited Sectoral Relevance and Peer Positioning

The sector relevance of Indoco Remedies is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other pharma manufacturers. As part of this industry, the company’s strategic positioning connects formulations and APIs to patients and healthcare providers across India and globally. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Cipla Limited, Torrent Pharmaceuticals Limited, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, and Mankind Pharma Limited. Firms with parallels in either product range or manufacturing scale are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Indoco Remedies P/E ratio have shown variations over different periods. The mean historical P/E Ratio over the last ten years has fluctuated significantly. The current P/E ratio stands at approximately 36.9-37.6 across different sources, while the industry P/E stands at approximately 29.9. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction.

Similarly, Indoco Remedies EPS has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and new product introductions supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material price volatility and competitive pressures have moderated EPS momentum. Indoco Remedies earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. The diluted EPS has shown growth, with TTM EPS of ₹8.0 as of September 2025.

Indoco Remedies market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market. Over years, the Indoco Remedies market cap has followed a pattern of growth followed by moderation. The market cap increased from approximately ₹5,376 crore in 2024 to ₹5,505 crore in 2025. As of April 2026, the Indoco Remedies market cap stands at approximately ₹1,830-3,910 crore across different sources. This fluctuation mirrors the trend in the Indoco Remedies share price and the broader performance of the pharmaceutical sector relative to broader market indices.

Indoco Remedies earnings over the past several years have been characterised by a period of growth followed by recent moderation. Total revenue decreased from ₹1,799.32 crore in FY2024 to ₹1,536.67 crore in FY2025, a decline of 14.6%. Profit After Tax decreased from ₹119.33 crore in FY2024 to a loss of ₹5.59 crore in FY2025. For the trailing twelve months (TTM) as of September 2025, net profit was ₹99.00 crore. For the quarter ended December 2025, net sales were ₹400.51 crore, up 7.38% from the previous quarter, with a net loss of ₹25.43 crore.

Indoco Remedies EPS has shown variation over the past decade. The diluted EPS stood at ₹-2.33 in FY2025, compared to ₹10.51 in FY2024. The EPS growth rate has shown significant variation, with the company delivering a growth rate of 36% in Q2 FY25 but a decline in FY25 overall.

The Indoco Remedies P/E ratio has shown fluctuations over the available period. At the end of recent fiscal years, the P/E ratio varied, with current levels at 36.9-37.6x across different sources, while the industry P/E stands at approximately 29.9x. The mean historical P/E ratio over the last five years has been in the range of 25-35x. The current P/E ratio compared to the historical average reflects that investor expectations are adjusting to near-term earnings momentum. The Indoco Remedies share price has been influenced by these valuation metrics. The Indoco Remedies stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Indoco Remedies Limited is a leading pharmaceutical company listed on both the NSE and BSE, where the Indoco Remedies share price reflects pharma demand cycles, regulatory approvals, and raw material costs within the healthcare sector. Its representation on stock exchanges supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical industry themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharma market.